Using systems biology approaches to elucidate cause and effect in host-microbiome interactions by Witherden, Elizabeth Anne et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.coisb.2017.05.003
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Witherden, E. A., Moyes, D., Bruce, K., Ehrlich, S., & Shoaie, S. (2017). Using systems biology approaches to
elucidate cause and effect in host-microbiome interactions. Current Opinion in Systems Biology, 141-146.
https://doi.org/10.1016/j.coisb.2017.05.003
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
Using systems biology approaches to elucidate cause and effect in host-microbiome
interactions
Elizabeth A. Witherden, David L. Moyes, Kenneth D. Bruce, Stanislav D. Ehrlich,
Saeed Shoaie
PII: S2452-3100(17)30002-1
DOI: 10.1016/j.coisb.2017.05.003
Reference: COISB 62
To appear in: Current Opinion in Systems Biology
Received Date: 6 February 2017
Accepted Date: 5 May 2017
Please cite this article as: Witherden EA, Moyes DL, Bruce KD, Ehrlich SD, Shoaie S, Using systems
biology approaches to elucidate cause and effect in host-microbiome interactions, Current Opinion in
Systems Biology (2017), doi: 10.1016/j.coisb.2017.05.003.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Title: 
Using systems biology approaches to elucidate cause and effect in host-microbiome 
interactions 
 
Authors: 
Elizabeth A. Witherden
1
, David L. Moyes
1
, Kenneth D. Bruce
1
, Stanislav D. Ehrlich
1,2 
and 
Saeed Shoaie
1,3,*
 
 
Author Affiliations: 
1
 Centre for Host–Microbiome Interactions, Dental Institute, King’s College London, London, 
SE1 9RT, United Kingdom.  
2
 Metagenopolis, Institut National de la recherché Agronomique, 78350, Jouy en Josas, 
France.  
3
 Centre for Translational Microbiome Research, Department of Microbiology, Tumor and 
Cell Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden 
* Corresponding author  
All authors contributed equally. 
 
Corresponding Author Details: 
Email: saeed.shoaie@kcl.ac.uk, phone: (+44) 0207 188 4362 
 
Abstract: 
The human microbiome is a diverse and complex ecosystem integral for healthy human 
development. Recent advances in next-generation sequencing technology have paved the 
way for a ‘multi-omics’ era of microbiome research, uncovering associations between 
microbial dysbiosis and disease. Our ability to harness the full potential of these ‘multi-
omics’ datasets are currently constrained by several technical, analytical, computational and 
bioinformatics factors. However, it may be possible to overcome such limitations through 
the use of novel systems biology thinking and approaches, to integrate and analyse these 
large ‘multi-omics’ datasets. Thus, the question arises - can systems biology approaches 
pave the way to a new era in microbiome research; determining underlying mechanisms in 
health and disease, and identifying key microbial interactions and causalities? 
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Introduction: 
The past decade has been a golden age for microbiome research. Advances in next-
generation sequencing and bioinformatics techniques have set the stage for ‘multi-omics’ 
approaches for studying the human microbiome in both health and disease [1,2]. Multi-
omics approaches extend beyond “traditional” microbial diversity and composition analysis 
as generated by 16S rRNA data sets, advancing into metagenomics, host-microbial 
interactions, and functional modelling with the aim of elucidating disease causalities [1,3-6]. 
These advances are all underpinned by bacterial ecology and systems biology concepts, 
which have been adapted to characterize and fully elucidate the role of the human 
microbiome in health and disease.  
To-date, systems-level approaches have focused on genome reconstructions, where 
genome-scale models have been built to model the functional relationships of highly 
abundant microorganisms within an ecosystem [7,8].  In these models, whole-genome 
assembly data is used in an attempt to link annotated genes to functional categories, 
functional gene networks, host-microbial interactions, and microbial-microbial interactions 
[3]. Such approaches, however, rely heavily on the quality of genome sequences and the 
availability of curated genome databases, as well as the quality of gene and genome 
annotation data. Here we discuss the current state of metagenomics research in the context 
of ‘multi-omics’ analysis and systems biology. 
 
Main Text: 
Advances in next-generation sequencing technology, have led to the establishment of the 
field of metagenomics. In its simplest form, metagenomics refers to the study of the genetic 
material recovered directly from the totality of organisms present in an environmental 
sample or microbial community [9]. In metagenomic studies, genomic DNA is isolated from 
the sample of interest, and randomly sheared before being shot-gun sequenced. The 
resulting output is a mass of short sequencing reads that need to be "trimmed" for quality, 
assembled, and mapped to gene databases allowing identification of the microbial 
population structure (taxonomy) and function (gene annotations). Despite there being 
numerous platforms available for metagenomic sequencing (Ie. Illumina, Ion Proton), there 
is a bottle neck for metagenomic studies in the lack of downstream resources for read 
mapping and subsequent bioinformatics analysis of the generated datasets. 
 
< Developing Reference Gene Catalogues > 
In the early 2000’s, international initiatives; the Human Microbiome Project (HMP) [10,11], 
and the International Human Microbiome Consortium (IHMC) [2], were established to 
generate sequencing resources that would aid in the characterisation of the human 
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microbiome. One of the main aims of these initiatives was to generate and curate genome 
databases for taxonomic discrimination of microbial communities, as well as mapping and 
annotating a large number of entire microbial genomes (Figure 1A) [10]. To date, even 
though there are several well established 16S rRNA gene databases (ie. SILVA  [12], 
Greengenes [13]) which can be used for taxonomic binning of sequencing reads, the curated 
resources available for analysing metagenomics and ‘multi-omics’ datasets have been 
limited. Reference gene catalogues are, however, becoming increasingly available - albeit 
primarily focused on the bacterial constituents of the gut microbiome in humans [10,14,15], 
and other mammals [16-18].  
In 2010, the first of these microbial gene catalogues for the human gut metagenome was 
published [14]. This catalogue contained 3.3 million non-redundant microbial genes, 99.91% 
of which represented genes of bacterial origin, with the remainder of archaeal, eukaryotic 
or viral origin [14]. Generated from data obtained by sequencing faecal samples from 124 
European individuals, this gene catalogue was estimated to cover the entire genomes of up 
to ~1,000 of the dominant bacterial species identified in the human gut [14]. Li and 
colleagues [15] built on this work by curating a human gut reference catalogue containing 
9,879,896 genes [15]. This Integrated Gene Catalogue (IGC) composes near complete sets of 
genes from the most abundant gut microbes identified in individuals from three continents 
[15]. Although, this catalogue is considerably more complete than the previous gut 
catalogues of Qin [14] and HMP [10,11], it is still primarily focused on the bacterial 
constituents of the gut microbiome. Until a curated gene catalogue representing gut 
bacterial, archaeal, viral and fungal genes and genomes is established, the full potential of 
microbiome research will not be realised [19]. Analogously, there is a need to establish 
reference gene catalogues specific for other body sites including the oral cavity, skin, and 
vagina [19]. The paucity of genes and genomes from non-bacterial origins in these 
catalogues means that despite covering many of the genes present in the microbiome, 
current catalogues under-represent many distinct gene families from entirely different 
evolutionary paths - e.g. eukaryotic genes. Further, although these catalogues are now 
being created and curated, the next big question is what do we do with this data to achieve 
its maximum potential? As we begin to answer this, we need to develop a variety of systems 
biology tools and platforms to take us in to the next phase of analyses. 
 
< Application of Systems Biology Approaches to study Host-Microbiome Interactions > 
Microbiome association studies have shown links between certain microorganisms and 
chronic conditions including Type 2 Diabetes [20,21], liver cirrhosis [22] and colon cancer 
[23]. None, however, have moved beyond this and elucidated the causalities [20-23]. There 
is now great interest in using systems biology approaches to elucidate the causalities 
between microbial species and their individual contribution to the overall ecosystem’s 
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phenotype and interactions with diet and host [24]. Key in the systems biology are genome 
scale models. 
Genome-scale models are the common denominator of systems biology, and have been 
applied as a powerful scaffold to identify the genotype-phenotype relationships in both 
individual bacterial species and microbial communities [25]. These models are set up to 
describe the complex cellular functions through the integration of ‘multi-omics’ data and 
specific objective-functions. Reconstruction of Genome-scale metabolic Models (GEMs) has 
become well-established over the last decade for a variety of microbial species and host 
tissues/cell line interactions [26-28]. Since most of the bacterial species in the human 
microbiome are typically challenging to culture in vitro, mainly bottom-up reconstruction 
methods have been used.  Genome sequences and similarity based annotations are the 
main data input required for such reconstructions. As Figure 1B illustrates, GEMs consist of 
biochemical reactions with their gene-protein associations of the target organism. For 
mathematical representations of GEMs, the stoichiometric coefficients are used to construct 
a stoichiometric (S) matrix. Rows and columns in the S matrix consist of “all” the involved 
metabolites and reactions in the network. The S matrix plays a key role in different systems 
biology tools and applications since it enables the mathematical formulation of the different 
biological networks. Several GEMs have been reconstructed in bottom-up approaches for 
bacteria that are constituents of different human microbiomes. In this regard, having a well-
established gene catalogue and integrating it with ‘multi-omics’ data forms an important 
complement to high-quality systems biology models. Unfortunately, GEMs are currently 
only applied to microbial networks, although a limited number of studies are beginning to 
integrate microbial datasets with both host and fungal networks.  
Figure 1C shows a GEM as a well-connected network that can be applied for network 
dependent analysis using ‘multi-omics’ data or through constraints implementation assisting 
in determining the phenotypic potential of a target organism. GEMs are widely applied in 
constraint-based modelling, referred to as Flux Balance Analysis (FBA), to predict and 
interpret physiological data and moreover, used in design and discovery [29,30]. Like host 
modelling, the application of microbiome GEMs has been mainly evolved in two paths. 
Using the network properties and contextualizing of high-throughput data through mapping 
‘multi-omics’ data to GEM to identify reporter metabolites and/or sub-networks [31,32]. 
Another path is applying constraint-based modelling to predict the cellular phenotypes[33].  
Using both applications in microbiome studies, has made it possible to elucidate the 
interactions between different microbial species, and the overall contribution of individual 
microorganisms to microbiome metabolism, host phenotype and nutrients uptake [34]. 
Generating GEMs for bacteria from the predominant taxa identified in the human 
microbiome and subsequently performing FBA to predict interactions, demonstrated how 
the gut microbiome and diet interact and influence amino acid profiles seen in the plasma 
[34,35]. This modelling approach can be validated using the data from mono and co-
colonized bacteria in germ free mice. Several optimization algorithms have been created to 
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predict the interactions between individual, while the overall microbial community and each 
bacterium are optimized [33,34,36]. This type of community and systems-level optimization 
has been applied to the human gut microbiome and successfully predicted the profile of key 
metabolites in faeces and plasma [34]. Further, this approach has been applied to 
determine the best diet to "improve" a host phenotype using the abundances of an 
individual’s gut microbiome. In addition, compartmentalizing the microbiome metabolism 
based on each species, enables integrative analyses using transcript data and the 
investigation of how transcriptional responses between microorganisms within the 
community vary in different conditions. Such analyses allow for the identification of 
different diagnostic biomarkers and novel therapeutic targets for metabolic diseases that 
are associated with the microbiome (Figure 1D)[37]. 
 
Nowhere is the new world of possibilities being opened up by GEMs and other modelling 
analysis techniques more evident than in the genesis of explorations of the antimicrobial 
resistance gene (ARG) profile of a microbiome, otherwise known as the "resistome" [38]. 
Between 2005 and 2010, there were 28 papers mentioning resistome on Pubmed. In 
contrast, the next 5 years (2011 - 2015) had 150 papers with almost two thirds of these 
investigating the resistome in the environment. In 2016 alone, there were 92 papers with 
half now relating to the resistome in host organisms.  
Analysis of the resistome relies on the gene sequence detail that is increasingly available via 
metagenomics to define the presence and abundance of specific gene sets representing the 
resistome. This provides an ability to track the development and spread of specific 
antimicrobial resistance genes through different communities and habitats [39-41]. Whilst it 
may seem counter-intuitive to be using GEMs in analysing the resistome, given the 
involvement of these genes in resistance to antimicrobial drugs, however, if we consider 
what many of these genes are predominantly involved in, the use of GEMs becomes more 
obvious when we realise the primary function for many of these genes.  Although they are 
important for resistance to antimicrobial drugs, many of these genes in their unmutated 
form are either direct targets for these drugs, or involved in the cellular pathways targeted 
by these drugs.  Likewise, many of the targets for antimicrobial drugs are either directly or 
indirectly involved in metabolic pathways or other essential cellular processes. Thus, they 
are amenable to analysis in two different ways - both through analysis of the development 
and movement of these genes, as well as the pattern of the genes.  Using systems biology 
approaches such as GEMs to analyse the resistome has immense predictive power, for 
example in defining how our microbiota will affect our responses to xenobiotics (drugs, 
dietary compounds and toxins) [42]. As such, this moves well beyond a simple 
understanding of gene presence and abundance, and provides an unprecedented 
opportunity to examine the resistome transmission from the environment to human or 
animal hosts, and even between individuals, as well as the selection pressures and 
mechanisms of evolution of these genes within a community. Given the global concern 
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relating to antimicrobial resistance and its rapid spread, this represents a particularly 
important tool set [43]. As such, we are now beginning to explore the concepts of functional 
pools of genes within microbial communities, along with the potential for the transfer of 
these genes between different species and communities, as well as the way these pools of 
genes may change in dysbiotic conditions associated with host disease states.   
 
Conclusions: 
The current focus of human host-microbiome studies is centred around generating ‘multi-
omics’ datasets to investigate the role of the microbiome in human health and diseases. 
Generating such data is remarkably important in the microbiome field for understanding the 
interactions between microbes and their host. A recent study has used GEMs of host and 
microbiome data on conventionally raised and germ-free mice and showed that global 
metabolic differences in mice tissues was influenced by the gut microbiome [44]. This 
therefore highlights the benefits of systems biology approaches and its capabilities for 
describing mechanistic relationships in the microbiome and host-microbial interactions. This 
is a necessary step-forward in microbiome research allowing for a better explanation of the 
role of the microbiome in associated diseases. In this concept, Genome-scale metabolic 
science is a great platform to understand causalities, perform integrative analysis, 
simulations, design, discovery, clinical interventions.  
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interact with each other and host processes to deliver new compounds affecting efficacy of drugs or 
with toxic effects. 
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Figure 1 Caption: 
< A proposed framework for the integrative analysis of multi-omics microbiome data using 
genome-scale modelling to understand causality of the ecosystem and elucidate the 
interactions. > 
After microbiome sampling of healthy and diseased individuals, different high-throughput 
(HT) analysis can be applied to the samples (A). Metagenomic outputs assist in the 
construction of catalogues for reference genes at different human microbiome sites. All of 
the ‘multi-omics’ data sets generated are interpreted individually and the results will depict 
any associations between the microbiome and health and disease. Most microbiome studies 
focus on this particular area and their data can be used as an input to the GEMs 
reconstruction process. (B). Based on availability of whole genome sequence data for the 
target microorganism, a GEM can be generated. The high-quality reads can be used to 
construct gene and pathway summaries [45], and this needs to be implemented in the 
process of GEMs generation. Since the individual phenotypic knowledge for most of these 
microbes is missing, omics data is used to compile a set of metabolic tasks for evaluation 
and validation of GEMs functionality. (C). To perform simulations with GEMs, it is necessary 
to introduce an objective function and maximizing biomass yield is the most relevant one 
for microbes metabolic modelling. The steps for high quality GEMs reconstruction has been 
extensively reviewed in different articles [46]. FBA is applied to simulated-ready GEMs for 
microbiome to predict the target organism phenotype under certain constraints. GEMs, as 
fully connected and functional networks are a great platform to perform integrative analysis 
of clinical data for identification of relevant predictive biomarkers as well as novel 
therapeutic targets for microbiome associated diseases. (D). The GEMs’ generated 
hypothesis can be in the form of probiotic and prebiotic design or gene knock. In-vivo and 
in-vitro experiments would assist in evaluating the GEMs predictions at the first stage and 
the confirmed could be used for clinical trials. Using the generated GEMs on human 
tissue/cells, one can explore the effect of a generated hypothesis on human host physiology 
using the simulated-ready tissue/cell GEMs [47]. Overall, this proposed pipeline can 
effectively speed up the generation of specific diagnosis and treatments in microbiome 
studies, although it requires more dedicated data generation for constructing high quality 
models.  
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Title: 
Using systems biology approaches to elucidate cause and effect in host-microbiome 
interactions 
 
 
Highlights: 
 
• Metagenomic gene catalogues to include archaea, fungi and bacteria proposed. 
• System-level framework for processing multi-omics data sets developed.  
• Review of Systems Biology approaches for studying host-microbiome interactions.  
